Irinotecan Eugia

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Eugia, is a topoisomerase I inhibitor presented as an injectable for intravenous use. It is employed in the treatment of metastatic and advanced colorectal cancer in adult patients and is classified under ATC code L01XX02.

GNH USA supplies Irinotecan Eugia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. Our distribution network ensures consistent quality and regulatory compliance across EU and global markets.

Irinotecan Eugia is a topoisomerase I inhibitor used in colorectal cancer therapy. - Metastatic colorectal cancer: improves disease control and extends survival in patients with stage IV disease. - Advanced colorectal cancer: provides tumor reduction and symptom relief in patients with unresectable disease. - Colorectal cancer (post‑surgical recurrence): used as part of combination regimens to prevent further disease progression.

Irinotecan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea: often severe and may require antidiarrheal therapy. - Neutropenia: reduced white blood cell count increasing infection risk. - Nausea and vomiting: may be managed with antiemetics. - Fatigue: general tiredness experienced during treatment. - Alopecia: hair loss that is usually reversible. - Anemia: decreased red blood cell count causing fatigue.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count requiring urgent care. - Severe colitis: inflammation of the colon that can be life‑threatening. - Hepatotoxicity: liver enzyme elevations indicating possible liver injury. - Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis in rare cases.

Before initiating Irinotecan Eugia, clinicians should assess patient-specific risk factors and monitor for toxicity. - Baseline blood counts: obtain complete blood count to detect pre‑existing neutropenia. - Liver function: evaluate hepatic enzymes as impaired metabolism can increase toxicity. - Renal function: adjust monitoring for patients with renal insufficiency. - Pregnancy: category D – avoid use unless benefits outweigh potential fetal risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Irinotecan's efficacy and safety can be altered by concomitant medications.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce SN‑38 formation and diminish therapeutic effect. - UGT1A1 inhibitors (e.g., atazanavir): can increase SN‑38 exposure, raising risk of severe neutropenia.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): increased bleeding risk due to mucosal damage. - Other myelosuppressive agents (e.g., cyclophosphamide): may exacerbate bone‑marrow suppression. - Antiemetics containing serotonin antagonists: monitor for serotonin syndrome when combined with serotonergic drugs.